414 related articles for article (PubMed ID: 30291373)
21.
Lasnon C; Majdoub M; Lavigne B; Do P; Madelaine J; Visvikis D; Hatt M; Aide N
Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2324-2335. PubMed ID: 27325312
[TBL] [Abstract][Full Text] [Related]
22. Current Evidence on PET Response Assessment to Immunotherapy in Lymphomas.
Lopci E; Meignan M
PET Clin; 2020 Jan; 15(1):23-34. PubMed ID: 31735299
[TBL] [Abstract][Full Text] [Related]
23. Segmental
Spadafora M; Pace L; Mansi L
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):1-4. PubMed ID: 27695909
[No Abstract] [Full Text] [Related]
24. Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT.
Nobashi T; Baratto L; Reddy SA; Srinivas S; Toriihara A; Hatami N; Yohannan TK; Mittra E
Clin Nucl Med; 2019 Apr; 44(4):e272-e279. PubMed ID: 30688730
[TBL] [Abstract][Full Text] [Related]
25. PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions.
Unterrainer M; Ruzicka M; Fabritius MP; Mittlmeier LM; Winkelmann M; Rübenthaler J; Brendel M; Subklewe M; von Bergwelt-Baildon M; Ricke J; Kunz WG; Cyran CC
Eur Radiol Exp; 2020 Nov; 4(1):63. PubMed ID: 33200246
[TBL] [Abstract][Full Text] [Related]
26. Comment on: "FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging, version 1.0".
Saboury B; Torigian DA; Alavi A
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1430-1; author reply 1432-3. PubMed ID: 20503048
[No Abstract] [Full Text] [Related]
27. Role of Optimal Quantification of FDG PET Imaging in the Clinical Practice of Radiology.
Ziai P; Hayeri MR; Salei A; Salavati A; Houshmand S; Alavi A; Teytelboym OM
Radiographics; 2016; 36(2):481-96. PubMed ID: 26963458
[TBL] [Abstract][Full Text] [Related]
28. Dual-Energy Computed Tomography-Based Iodine Quantitation for Response Evaluation of Lung Cancers to Chemoradiotherapy/Radiotherapy: A Comparison With Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography-Based Positron Emission Tomography/Computed Tomography Response Evaluation Criterion in Solid Tumors.
Ren Y; Jiao Y; Ge W; Zhang L; Hua Y; Li C; Zhai W; Tang X; He W; Fang M; Zheng X
J Comput Assist Tomogr; 2018; 42(4):614-622. PubMed ID: 29613988
[TBL] [Abstract][Full Text] [Related]
29. The role of
Narayanan P; Sahdev A
Br J Radiol; 2017 Nov; 90(1079):20170283. PubMed ID: 28830238
[TBL] [Abstract][Full Text] [Related]
30. Examining Immunotherapy Response Using Multiple Radiotracers.
Goggi JL; Hartimath SV; Hwang Y; Tan YX; Khanapur S; Ramasamy B; Jiang L; Yong FF; Cheng P; Tan PW; Husaini MA; Yuen TY; Jieu B; Chacko AM; Larbi A; Renia L; Johannes C; Robins EG
Mol Imaging Biol; 2020 Aug; 22(4):993-1002. PubMed ID: 32006204
[TBL] [Abstract][Full Text] [Related]
31. Present and future role of FDG-PET/CT imaging in the management of breast cancer.
Kitajima K; Miyoshi Y
Jpn J Radiol; 2016 Mar; 34(3):167-80. PubMed ID: 26733340
[TBL] [Abstract][Full Text] [Related]
32.
Birk Christensen C; Loft-Jakobsen A; Munck Af Rosenschöld P; Højgaard L; Roed H; Berthelsen AK
Clin Physiol Funct Imaging; 2018 Mar; 38(2):278-284. PubMed ID: 28168798
[TBL] [Abstract][Full Text] [Related]
33. Update 2018: 18F-FDG PET/CT and PET/MRI in Head and Neck Cancer.
Sanli Y; Zukotynski K; Mittra E; Chen DL; Nadel H; Niederkohr RD; Subramaniam RM
Clin Nucl Med; 2018 Dec; 43(12):e439-e452. PubMed ID: 30394934
[TBL] [Abstract][Full Text] [Related]
34. Role of interim
Cremonesi M; Gilardi L; Ferrari ME; Piperno G; Travaini LL; Timmerman R; Botta F; Baroni G; Grana CM; Ronchi S; Ciardo D; Jereczek-Fossa BA; Garibaldi C; Orecchia R
Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1915-1927. PubMed ID: 28681192
[TBL] [Abstract][Full Text] [Related]
35. Radiotherapy response evaluation using FDG PET-CT-established and emerging applications.
Cliffe H; Patel C; Prestwich R; Scarsbrook A
Br J Radiol; 2017 Mar; 90(1071):20160764. PubMed ID: 28008773
[TBL] [Abstract][Full Text] [Related]
36. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000.
Reske SN; Kotzerke J
Eur J Nucl Med; 2001 Nov; 28(11):1707-23. PubMed ID: 11702115
[TBL] [Abstract][Full Text] [Related]
37. FDG PET/CT in oncology: "raising the bar".
Patel CN; Goldstone AR; Chowdhury FU; Scarsbrook AF
Clin Radiol; 2010 Jul; 65(7):522-35. PubMed ID: 20541652
[TBL] [Abstract][Full Text] [Related]
38. The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy.
Wong ANM; McArthur GA; Hofman MS; Hicks RJ
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):67-77. PubMed ID: 28389693
[TBL] [Abstract][Full Text] [Related]
39. Longitudinal studies of the
Sachpekidis C; Anwar H; Winkler JK; Kopp-Schneider A; Larribere L; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
Cancer Immunol Immunother; 2018 Aug; 67(8):1261-1270. PubMed ID: 29872898
[TBL] [Abstract][Full Text] [Related]
40. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
